1 Department of Internal Medicine V and 2 Institute of Human Genetics, University of Heidelberg; 3 Central Unit Biostatistics, German Cancer Research Center, Heidelberg; 4 Department of Hematology and Oncology, Staedt. Kiniken Bielefeld GmbH, Germany
* Correspondence to: Dr Marc S. Raab, Department of Internal Medicine V, University of Heidelberg, INF 410, D-69120 Heidelberg, Germany. Tel: +49-6221-568072; Fax: +49-6221-565609; Email: marc.raab{at}med.uni-heidelberg.de
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Patients and methods: The aim of this study was to find the most sensitive real-time PCR assay (TaqMan), based on the IGH rearrangement, to quantify the tumour load of 11 patients with multiple myeloma after non-myeloablative allogeneic transplantation. Patient-allele specific primers (ASO) and the TaqMan probe were derived from CDR2 and CDR3 hypervariable regions of IGH, while consensus primers were located within the FR3 and FR4/JH regions. Four different approaches of primer combinations were tested.
Results: ASO-forward and -reverse primers together with the clone-specific TaqMan probe were the most sensitive approach compared with the JH (P=0.071) or the FR3 consensus primer (P <0.001). The detection limit amounted to 1/1041/105 cells. Consecutively, 120 samples from 11 patients prior and post allogeneic transplantation were analysed. Three patients reached complete clinical remission accompanied by molecular remission. Disease progression or relapse was seen in six patients. In five, molecular progressive disease was detected prior to the clinical diagnosis of progression or relapse.
Conclusion: Patient-specific real-time IGH-PCR provides the opportunity for earlier treatment intervention.
Key words: IgH rearrangement, minimal residual disease, multiple myeloma, non-myeloablative allogeneic transplantation, real-time PCR
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
TaqMan real-time PCR was performed with patient-specific (allele specific oligo, ASO) and consensus primers and probes derived from CDR2, CDR3 and J regions as described below. The concentration of each primer and probe was optimised for each assay. Amplification and fluorescence detection were carried out on the ABI Prism 7700 SDS analytical thermal cycler (Applied Biosystems, Weiterstadt, Germany). Forty-five cycles of PCR were performed. The cycle threshold (CT) is known as the cycle in which fluorescent emission reaches 10-fold the basal emission, a value that is proportional to the copy number of the target gene. Patient-specific standard curves were prepared by serial 10-fold dilutions of the plasmid DNA containing the tumour-specific VDJ sequence starting from 105 to 10 copies in a background of 600 ng of polyclonal genomic DNA. An independent BCL-2 quantitative TaqMan assay was performed for each patient to normalise each sample for DNA content by dividing IGH copies with the mean number of BCL-2 copies. Each reaction was carried out in triplicate.
Strategies of ASO and consensus primer design
Different strategies for the use of primers and probes located in the highly variable as well as in the conserved regions have been reported [12, 19
22
]. Determination of the specific and most sensitive approach has not been addressed yet. Involvement of the most variable CDR3 region, at least for the fluorogenic probe, was assumed to be necessary to reach sufficient sensitivity in patients after allogeneic transplantation. Therefore patient-specific ASO primers and the TaqMan probe were derived using the CDR2 (forward primer) and CDR3 (reverse primer/probe) hypervariable regions of the IGH rearrangement, while the consensus primers were located within the FR3 (forward primer FR3A) and FR4/JH (reverse primer LJH) region [17
, 18
]. The median CT-value of serial 10-fold dilutions of 16 different clone-specific plasmids in polyclonal genomic DNA was assessed for each of the following approaches (Figure 1): (A) ASO-forward/ASO-reverse primer, (B) ASO-forward/consensus reverse primer, (C) consensus forward/ASO-reverse primer and (D) consensus forward/consensus reverse primer.
|
Chimerism analysis
After nucleic acid extraction, as described above, small tandem repeats were amplified and analysed. PCR was performed using the Amp-FISTR Profiler PCR amplification kit (Applied Biosystems, Weiterstadt, Germany) as recommended by the manufacturer. Separation and detection of the amplified PCR products was done on an ABI 310 automated sequencer (Applied Biosystems). The analysis of the results was performed using the Genescan 2.1 software (Applied Biosystems). The threshold for quantification of the ratio of donor/recipient chimerism was 2.5%.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
After allogeneic transplantation two patients (HM and SH) achieved clinical complete remission (CCR) on day +39 and +177, respectively. One additional patient (BG) remained in continued pre-transplant CCR. These three patients converted to molecular remission post-allo SCT on day +39 (HM, three BM and six PB samples revealing PCR negativity), +177 (SH, two BM and one PB samples) and +71 (BG, two BM and nine PB samples). Two of these patients (SH and BG) are currently in long-term CCR with last clinical data from day +440 and +1298, respectively. One patient (HM) relapsed after achieving a complete remission. Treatment with steroids and DLI resulted again in CCR and molecular remission.
Another three patients (BH, FK, TR) remained in partial response (PR) (last clinical data from day +364, +567 and +867, respectively) with a tumour load in BM between 0.005% and 0.5% (11 samples) while no tumour load was detectable in PB (nine samples).
Five patients (BK, HH, MK, SW, VP) experienced progressive disease (PD), diagnosed by an increase of the monoclonal protein post allo SCT on day +290, +118, +31, +57 and +189, respectively. One relapsed on day +116 (HM, as mentioned above). Figure 3 depicts the clinical and molecular follow-up of the six patients with PD or relapse. By molecular follow-up, an increase of tumour load was detected in five of these cases, on day +100 in PB confirmed by a second PB sample on day +171 for patient BK, on day +95 in PB confirmed by BM on day +109 (HM), on day +27 in BM and PB (HH), on day +30 in BM confirmed by a second BM sample on day +56 (SW) and on day +30 confirmed by BM and PB on day +56 (VP). Thus, the first increase of the malignant plasma cell clone preceded the clinical diagnosis of PD by a median of 95 days (range, 21190).
|
According to this definition, molecular PD (BK, HH, SW, VP) or relapse (HM) could be detected 119, 91, 1, 133 and 7 days, respectively, before PD was diagnosed clinically by kinetics of the monoclonal protein (Figure 3). The remaining patient (MK) entered early clinical PD at day +31 after transplantation due to increase of urine light chain excretion. At that time, the patient showed a persistently high amount of BM tumour load of 9.6%. However, molecular PD could not be clearly diagnosed according to the above mentioned criteria.
After diagnosis of clinical PD, five patients received steroids (BK, HH, HM, SW, VP), in two cases followed by DLI (SW and HM). After DLI, a significant reduction of tumour load was observed, with patient HM entering CCR and molecular remission again, accompanied by extensive intestinal Graft-versus-Host disease (GvHD) (WHO grade III) with fatal outcome. For the remaining patient (MK) immunosuppression was reduced as sole measure, resulting in an ongoing reduction of tumour load accompanied only by mild GvHD of the skin (WHO grade I) and an overshooting polyclonal production of immunoglobulin (Figure 3).
In summary, we were able to detect molecular PD preceding clinical PD or relapse in five out of six patients. Furthermore, all patients of this study in whom an increase of tumour load was recognised by molecular follow-up after allo SCT eventually went into clinical PD.
Recipient/donor chimerism and correlation to the tumour load
Each of the 41 BM and 56 PB follow-up samples obtained after allo-SCT was analysed for the percentage of recipient/donor chimerism. Patients in CCR achieved full donor chimerism (FDC) in the bone marrow on days +252 (BG) and +177 (SH), while the patient relapsing from CCR (HM) never reached FDC (best <2.5%, day +67). Those in PR showed constant low level recipient chimerism of <2.5% with two of them (FK, TR) reaching FDC on days +221 and +307, despite a detectable tumour load in the BM. However, no clear correlation of recipient/donor chimerism and tumour load kinetics was observed in patients with PD or relapse (data not shown).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Gerard et al. [28] first showed the feasibility of real-time IGH PCR assays to quantitate residual myeloma cells in clinical samples after high-dose therapy and ABSCT. Thereafter, several studies determined the kinetics of tumour cells after ABSCT as well as allogeneic transplantation. In these studies different approaches of primer and probe design were used, such as ASO-forward primer and probe/JH consensus reverse primer [18
], ASO-forward primer/JH consensus reverse primer and probe [21
], ASO primers/FR3 consensus probe [21
], ASO primers and probe [12
]. Each of these groups reported a sensitivity of 104105. However, a comparison of the different strategies has not been reported yet.
In the present study, we found the most sensitive approach of primer and probe design using forward and reverse patient-specific primers derived from the CDR2 and CDR3 regions, the latter representing the most variable part of the IGH sequence in which we located our patient-specific fluorescent probe as well. Compared to consensus forward primers (FR3A) within the FR3 region replacing the ASO-forward primer (P <0.001), JH region consensus primers (LJH) replacing the ASO-reverse primer showed just a slightly lower sensitivity (P=0.071). When analysing the individual clonal sequences with respect to the primer sequence, all but one showed at least one base-pair mismatch in the FR3 region. One clone-specific plasmid containing an FR3 region matching the FR3A consensus sequence showed comparable CT results for strategy C and strategy B.
Molecular remission assessed by non-quantitative ASO-PCR has been reported to be achieved after myeloablative allogeneic transplantation [11, 29
31
] and to predict superior relapse-free survival [11
]. Recently, the group of Voena et al. [12
] reported the feasibility of real-time PCR to evaluate the GvM effect after allogeneic transplantation following conventional myeloablative conditioning in three patients. The assessment of molecular remission and kinetics of residual myeloma cells in the non-myeloablative setting has not been described yet.
In order to characterise the kinetics of myeloma cells after non-myeloablative allogeneic transplantation, we used strategy A for evaluating 120 patient samples. We report the molecular follow-up of 11 patients with focus on progressive disease or relapse of six cases after allo SCT. In five of these cases a molecular progression of the disease could be detected prior to clinical onset of PD/relapse. However, in two cases this succeeded only a few days before PD was diagnosed clinically, due to a lack of appropriately timed samples.
One patient went into clinical PD shortly after allo SCT accompanied by a high level of tumour load. Reduction of immunosuppression led to an ongoing decrease of clonal genomes, indicating an enabled GvM effect.
In summary, our findings demonstrate that (i) real-time PCR can provide a useful tool to detect molecular PD prior to clinical PD allowing early treatment intervention such as DLI, and (ii) patients with stable molecular tumour load without signs of PD could benefit from optimising immunotherapeutic intervention to maintain curative activity while minimising the associated side effects.
Prospective studies should evaluate if the monitoring of molecular disease can guide early post-transplant therapeutic intervention, reduce life-threatening side-effects and prevent clinical relapse or PD.
![]() |
Acknowledgements |
---|
Received for publication June 19, 2004. Revision received November 24, 2004. Accepted for publication November 29, 2004.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 2032.
3. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 5565.
4. Child JA, Morgan GJ, Davies FE et al. for the Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 18751883.
5. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 198393 and 19948 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209216.[CrossRef][ISI][Medline]
6. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 13121322.[Abstract]
7. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 12951303.
8. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755760.
9. Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 7582.
10. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 30313037.
11. Corradini P, Cavo M, Lokhorst H et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 19271929.
12. Voena C, Malnati M, Majolino I et al. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 791793.[CrossRef][ISI][Medline]
13. Cremer FW, Ehrbrecht E, Kiel K et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 2000; 26: 851858.[CrossRef][ISI][Medline]
14. Lipinski E, Cremer FW, Ho AD et al. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 957962.[CrossRef][ISI][Medline]
15. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 3: 842854.
16. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 11151123.[CrossRef][ISI][Medline]
17. Brisco MJ, Tan LW, Orsborn AM, Morley AA. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 1990; 75: 163167.[ISI][Medline]
18. Aubin J, Davi F, Nguyen-Salomon F et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995; 9: 471479.[ISI][Medline]
19. Rasmussen T, Poulsen TS, Honore L, Johnsen HE. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay. Exp Hematol 2000; 28: 10391045.[CrossRef][ISI][Medline]
20. Ladetto M, Donovan JW, Harig S et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241253.[ISI][Medline]
21. Willems P, Verhagen O, Segeren C et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood 2000; 96: 6370.
22. Togel F, Kroger N, Korioth F et al. Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR. J Hematother Stem Cell Res 2002; 11: 971976.[CrossRef][ISI][Medline]
23. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2003.
24. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20: 40224031.
25. Maloney DG, Molina AJ, Sahebi F et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 34473454.
26. Luft T, Moos M, Goldschmidt H, Ho AD, Gorner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646653.[CrossRef][ISI][Medline]
27. van Rhee F, Lin F, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 33773383.
28. Gerard CJ, Olsson K, Ramanathan R, Reading C, Hanania EG. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards. Cancer Res 1998; 58: 39573964.[Abstract]
29. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208.
30. Martinelli G, Terragna C, Zamagni E et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000; 85: 930934.[ISI][Medline]
31. Martinelli G, Terragna C, Zamagni E et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: 22732281.
|